|1.||Richardson, Des R: 16 articles (10/2015 - 09/2004)|
|2.||Kalinowski, Danuta S: 8 articles (04/2015 - 01/2009)|
|3.||Kovacevic, Zaklina: 6 articles (10/2015 - 01/2013)|
|4.||Sahni, Sumit: 5 articles (04/2015 - 11/2013)|
|5.||Merlot, Angelica M: 4 articles (04/2015 - 12/2013)|
|6.||Jansson, Patric J: 4 articles (04/2015 - 01/2013)|
|7.||Richardson, D R: 3 articles (02/2013 - 01/2012)|
|8.||Lane, Darius J R: 2 articles (04/2015 - 04/2014)|
|9.||Pantarat, Namfon: 2 articles (04/2015 - 12/2013)|
|10.||Richardson, Vera: 2 articles (04/2015 - 01/2014)|
11/28/2014 - "These studies demonstrate that Dp44mT can overcome the prosurvival activity of autophagy in cancer cells by utilizing this process to potentiate cell death. "
01/01/2014 - "This study showed that a combined treatment with 2μM easily available Fe(II), Cu(II) and Zn(II) each and 5μM Dp44mT on eight different cancer cell lines resulted in a 10-40-fold increase in the intracellular Cu content compared to control samples. "
12/01/2013 - "Studies examining the tissue distribution of ¹⁴C-Dp44mT injected intravenously into a mouse tumor model demonstrated the ¹⁴C label was primarily identified in the excretory system. "
04/30/2015 - "Significantly, the HSA-mediated increase in the targeting of Dp44mT to cancer cells potentiated apoptosis and could be important for enhancing efficacy."
04/30/2015 - "Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) demonstrates potent anti-cancer activity. "
03/01/2009 - "Our results suggest that Dp44mT possesses potential as an effective cytotoxic agent for the chemotherapeutic treatment of acute leukemia."
03/01/2009 - "Furthermore, this study also showed that Dp44mT had broad activity, inducing apoptosis in several types of acute leukemia and also multiple myeloma cell lines. "
03/01/2009 - "Dp44mT acted to induce a G(1)/S arrest in NB4 promyelocytic leukemia cells at low concentrations (0.5-2.5 microM), being far more effective than the clinically used chelator, desferrioxamine (DFO). "
03/01/2009 - "Using acute leukemia cells, the effect of Dp44mT on apoptosis, cell cycle, caspase-3 activation, and mitochondrial trans-membrane potential has been examined by flow cytometry. "
|4.||Neoplasm Metastasis (Metastasis)
02/05/2013 - "Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells."
10/03/2006 - "Dp44mT caused up-regulation of the Fe-responsive tumor growth and metastasis suppressor Ndrg1 in the tumor but not in the liver, indicating a potential mechanism of selective anticancer activity. "
09/30/2014 - "The iron chelator Dp44mT up-regulated NDRG2, suppressed epithelial-mesenchymal transition (EMT) and inhibited tumor metastasis in HCC having high metastatic potential. "
09/30/2014 - "The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-Myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway."
01/01/2015 - "Here, we reveal how the iron-binding ligands desferrioxamine (DFO), di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC) inhibit constitutive and interleukin 6-induced activation of signal transducer and activator of transcription 3 (STAT3) signaling, which promotes proliferation, survival, and metastasis of cancer cells. "
|5.||Breast Neoplasms (Breast Cancer)
11/01/2011 - "Testing of the GI(50) profile of Dp44mT in the NCI-60 panel confirmed activity against breast cancer cells. "
02/01/2009 - "The results show that Dp44mT is cytotoxic to breast cancer cells, at least in part, due to selective inhibition of top2alpha. "
02/01/2009 - "Dp44mT alone induced selective cell killing in the breast cancer cell line MDA-MB-231 when compared with healthy mammary epithelial cells (MCF-12A). "
02/01/2009 - "We investigated the mechanism whereby Dp44mT kills breast cancer cells, both as a single agent and in combination with doxorubicin. "
02/01/2009 - "The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells."
|3.||di- 2- pyridylketone- 4,4- dimethyl- 3- thiosemicarbazone
|8.||Caspase 3 (Caspase-3)
|9.||STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)
|10.||Small Interfering RNA (siRNA)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)